CD22 and leukemia: Additionally, a structurally optimized CD19/CD22/CD3 TsAb demonstrated 100% survival in murine xenograft models, superior to blinatumomab or combination bispecific antibodies, and effectively cleared leukemia in the presence of CD19/CD22 antigen heterogeneity, highlighting its ability to prevent immune escape [67,68].